Azaepothilone B and its derivatives: a patent review

Expert Opinion on Therapeutic Patents

Volumn 26, Issue 8, 2016, Pages 891-905

  Mandhare, Anita ^a   Biradar, Satish ^a   Gurule, Asha ^a  

^a CSIR Unit for Research and Development of Information Products   (India)

Author keywords

antiproliferative; azaepothilone B; Breast cancer; cytostatic; epothilone B; microtubule stabilizing agent; Sorangium cellulosum

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 POLYPEPTIDE 4 INHIBITOR; CYTOCHROME P450 POLYPEPTIDE 5 INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DOXORUBICIN; EPOTHILONE A; EPOTHILONE B; IPILIMUMAB; IRINOTECAN; IXABEPILONE; KETOCONAZOLE; PACLITAXEL; TICILIMUMAB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; EPOTHILONE DERIVATIVE;

ADVANCED CANCER; ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BRAIN DISEASE; BRAIN TUMOR; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER RESISTANCE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COMBINATION DRUG THERAPY; DEGENERATIVE DISEASE; DRUG FORMULATION; DRUG POTENTIATION; DRUG SYNTHESIS; GALLBLADDER CANCER; GLIOMA; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; KAPOSI SARCOMA; KIDNEY DISEASE; METABOLIC DISORDER; MULTIPLE SCLEROSIS; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; VIRUS INFECTION; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; DRUG DESIGN; DRUG RESISTANCE; FEMALE; NEOPLASMS; PATENT; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; HUMANS; NEOPLASMS; PATENTS AS TOPIC;

EID: 84978765980     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1080/13543776.2016.1199688     Document Type: Article

References (88)

1. Gw Pharma Ltd. Phytocannabinoids for use in the treatment of breast cancer.US20140314757A1. 2014.
2. H.L.Chih Herbal composition for treating metastatic breast cancer.US20140295006A1. 2014.
3. J.O’Shaughnessy Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20–29.
4. Bipar Sciences, Inc. Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan.US20130274281A1. 2013.
5. M.Colozza, E.de Azambuja, F.Cardoso, et al. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist. 2006;11(2):111–125.
6. F.M.Palmieri, U.Hopkins. Ixabepilone, a new class of chemotherapy for advanced breast cancer. Cancer Therapy. 2004;7:153–162.
7. L.Vahdat. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. The Oncologist. 2008;13:214–221.
8. The University Of Utah Research Foundation. Paclitaxel trihydrates and methods of making thereof.US8633240B2. 2014.
9. E.Haar, R.J.Kowa Lski, E.Hamel, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than Taxol. Biochemistry. 1996;35:243–250.
10. T.Lindel, P.R.Jen Sen, W.Fenical, et al. Eleutherobin,a new cytotoxin that mimics paclitaxel (Taxol) by stabilizing microtubules. J Am Chem Soc. 1997;119:8744–8745.
11. K.C.Nicolaou, N.Winssinger, D.Vourloumis, et al. Solid and solution phase synthesis and biological evaluation of combinatorial sarcodictyin libraries. J Am Chem Soc. 1998;120:10814–10826.
12. P.Giannakakou, R.Gussio, E.Nogales, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. PNAS. 2000;97(6):2904–2909.
13. G.Hofle, N.Glaser, M.Kiffe, et al. N-Oxidation of Epothilone A–C and O-Acyl Rearrangement to C-19- and C-21-Substituted epothilones. Angew Chem Int Ed. 1999;38(13–14):1971–1974.
14. D.M.Bollag, P.A.McQueney, J.Zhu, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55:2325–2333.•• First time reported the cytotoxic activity of epothilones.
15. D.-S.Su, A.Balog, D.Meng, et al. Structure–activity relationship of the epothilones and the first in vivo comparison with paclitaxel. Angew Chem Int Ed Engl. 1997;36:2093–2096.
16. F.Y.Lee, R.Borzilleri, C.R.Fairchild, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 7:1429–1437.•• Similar mode of action but better efficacy than paclitaxel.
17. A.Florshmer, K.Altman. Epothilones and analogues – a new class of promising microtubule inhibitors. Expert Opin Ther Patents. 2001;11(6):951–968.
18. Ixempra. Rx List owned and operated by WebMD, USA. Available at http://www.rxlist.com/ixempra-drug.htm [Cited on Feb28, 2016]
19. C.Aghajanian, H.A.Burris, S.Jones, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol. 2007;25(9):1082–1088.
20. Ixempra. Bristol-Myers Squibb Co, USA. 2011. Available at http://packageinserts.bms.com/pi/pi_ixempra.pdf. [Cited onFeb28, 2016].
21. Bristol-Myers Squibb Co. Methods for the Preparation, Isolation and Purification of Epothilone B, and X-Ray Crystal Structures of Epothilone B. WO2004026254A1. 2004.
22. Bristol-Myers Squibb Company. A Process for the Preparation of Ring-Opened Epothilone Intermediates which are useful for the preparation of Epothilone Analogs.WO9927890A2. 1999.
23. Bristol-Myers Squibb Co. 12,13-Modified Epothilone Derivatives.WO9954319A1. 1999.
24. Bristol-Myers Squibb Co. Epothilone Derivatives.WO2002098868A1. 2002.
25. Bristol-Myers Squibb Co. Process for the Preparation of Epothilone Analogs.US6518421B1. 2003.•• Single-vessel reaction with increasing yield.
26. Bristol-Myers Squibb Co. Process for the reduction of oxiranyl epothilones to olefinic epothilones.US6320045B1. 2001.
27. Taizhou Jinzhao Weiye Fine Chem Ind Co Ltd. Method for biochemically synthesizing epothilone D-Lactam derivatives. CN101906099A. 2010.
28. Taizhou Jinzhao Weiye Fine Chemical Industry Co Ltd. Chemical synthesis method of epothilone B-Lactam derivative.CN101880284A. 2010.•• Total synthesis of azaepothilone B.
29. Xellia Pharmaceuticals Aps. Manufacturing of epothilone derivatives and the use thereof.WO2013008091A1. 2013.
30. Xellia Pharmaceuticals Aps, V.Bjoernstad, A.Heggelund Process for preparation of ixabepilone and intermediates useful in said process.WO2013164102A1. 2013.•• New process for synthesis of ixabepilone.
31. Kosan Biosciences Inc, G.Ashley, B.Metcalf. Epothilone derivatives and methods for making and using the same.US20030023082A1. 2003.
32. Y.Jialin. Synthetic method for natural product epsilon B lactam derivative.CN1554659A. 2004.•• New total synthesis process of azaepothilone B
33. Chengdu Mol Biopharmaceutical Co Ltd. Preparation method of epothilone B lactam derivatives.CN103936748A. 2014.
34. L.Tang, R.Qiu. Epothilone compounds, preparation method and use thereof.US2012322838A1. 2014.
35. Beijing Huahao Zhongtian Biotechnology Co. Ltd. Novel epothilones compound as well as preparation method and use thereof.CN101177425B. 2012.
36. Sloan-Kettering Institute for Cancer Research, USA. Synthesis of epothilones, intermediates thereto and analogues thereof. WO2001064650A2. 2001.
37. S.J.Danishefsky, et al. Synthesis of epothilones, intermediates thereto and analogues thereof.US20020058286A1. 2002.
38. Sloan-Kettering Institute For Cancer Research, S.J.Danishefsky, A.Rivkin, et al. Synthesis of epothilones, intermediates thereto, analogues and uses thereof.US7384964B2. 2008.•• First total synthesis process for azaepothilone B.
39. Shenzhen Jatie Pharmaceutical Co Ltd. Ixabepilone Total Synthesis.CN103275091A. 2013.
40. Bristol-Myers Co. Epothilone derivative. US6605599B1. 1999.
41. Scinopharm Taiwan, Ltd. process for ixabepilone, and intermediates thereof.WO2014136099A1. 2014.
42. Kosan Biosciences Inc, G.Ashley, M.Fardis, et al. Epothilone derivatives and methods for making and using the same.WO0192255A3. 2002.
43. A.G.Novartis Epothilone derivatives.US7317100B2. 2008.
44. A.M.Crasto. Polymorph case study… duvelisib [cited 2016 Feb28]. Available at http://newdrugapprovals.org/2015/08/31/polymorph-case-study-duvelisib/.
45. Bristol-Myers Squibb Company. Polymorphs of an epothilone analog.US7153879B2. 2006.• New polymorphs azaepothilone B by BMS.
46. Plus Chemicals Sa, Teva Pharmaceuticals USA Inc. Solid State forms of Ixabepilone.WO2011153221A1. 2011.
47. Zhejiang Hisun Pharm Co Ltd. Crystal form of Ixabepilone and the Preparation Method and Use Thereof.WO2014135043A1. 2014.
48. Schering AG, W.Skuballa, J.Gay, et al. radioactively labeled epothilone derivatives, method for the production thereof, and their biochemical and pharmaceutical use.WO0166154A2. 2001.• Radioactivity-labeled derivatives.
49. Schering AG. New 13-Halo Or cyano-epothilone derivatives are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease.DE10020517A1. 2001.
50. Schering AG. 6-Alkenyl-, 6-Alkinyl- and 6-Epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations.US2010168179A1. 2010.
51. Kosan Biosciences Inc. 14-Methyl-Epothilones.WO03045324A3. 2004.
52. ETH Zuerich, A.Karl-Heinz, F.Fabian, et al. 12-Aza-Ep0thil0nes, process for their preparation and their use as antiproliferative agents.WO2007110214A1. 2007.
53. P.Llc. Deuterium-enriched ixabepilone.US2009076099A1. 2009.•• Process for preparation of deuterium-enriched ixabepilone.
54. Bristol-Myers Squibb Co, R.Bandyopadhyay, T.Malloy, et al. Parenteral formulation for epothilone analogs.US7022330B2. 2002.
55. Bristol-Myers Squibb Co, T.Haby, U.S.Gogate, et al. Process and formulation containing epothilones and analogs thereof.US20050171167A1. 2005.
56. Bristol-Myers Squibb Co, Elan Pharma Int Ltd. Nanoparticle dispersion containing lactam compound.EP1773335A4. 2011.
57. Bristol Myers Squibb Co, V.Naringrekar, F.T.Comezoglu, et al. Methods for Administering Ixabepilone.WO2006105399A1. 2006.
58. Bristol-Myers Squibb Co. Enteric coated bead comprising ixabepilone.EP1817013B1. 2008.
59. Bristol-Myers Squibb Co. Pharmaceutical dosage forms of epothilones for oral administration.WO2002058701A1. 2002.•• Oral administration of anticancer drug.
60. Bristol-Myers Squibb Co, D.Lee, F.Y.Lee. et al. Oral administration of ixabepilone.WO2009089138A1. 2009.
61. Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery.WO2011031865A1. 2011.
62. Cerulean Pharma Inc, S.Eliasof. Compositions and Methods for Treatment of Autoimmune and Other Disease.US2012064107A1. 2012.
63. Cerulean Pharma Inc. Cyclodextrin-Based Polymers for Therapeutic Delivery.US2013196906A1. 2013.
64. Bayer Schering Pharma AG; K.,.C.Fischer. Functionalised solid polymer nanoparticles containing epothilones.WO2009074274A1. 2009.
65. Bayer Schering Pharma AG. Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer.EP2210584A1. 2010.
66. Abraxis Bioscience Inc; A.Yang, C.Tao, et al. Compositions and methods for the preparation and administration of poorly water soluble drugs.WO2006034147A3. 2006.
67. Bdr Pharm Int Pvt Ltd. Lyophilized ixabepilone pharmaceutical compositions.IN201400083I3. 2014.
68. Brilliant Biomedical Technology (Suzhou) Co. Ltd. Nobuyasu Pharmaceuticals (Suzhou) Co., Ltd. Ixabepilone albumin freeze-dried composition and preparation method thereof.CN103908432A. 2014.
69. Bristol-Myers Squibb Company, F.Y.Lee. Treatment of refractory tumors using epothilone derivatives.WO02066038A1. 2002.
70. Schering AG. Use of epothilones in the treatment of brain diseases associated with proliferative processes.EP1340498A1. 2003.•• Use of epothilones for neurodegenerative diseases.
71. Bristol-Myers Squibb Co. Methods for treating cancer in patients having breast cancer resistance protein overexpression.US20110112155A1. 2011.
72. Univ. Emory, Univ. Cornell, Virginia Tech Intell Prop, et al. Non-myelosuppressive compounds, pharmaceutical compositions thereof, and methods of treatment.WO2009146152A3. 2010.
73. Bristol-Myers Squibb Co, L.David, M.Voi, et al. Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases.WO03105828A1. 2003.
74. Bristol-Myers Squibb Co, F.Y.Lee. Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases.US7312237B2. 2007.
75. Bristol-Myers Squibb Co, M.Cohen. Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals.WO2007140299A3. 2008.
76. Bristol-Myers Squibb Co, M.Jure-Kunkel. Combination of Anti-Ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases.WO2009089260A3. 2009.
77. Bristol-Myers Squibb Co. Combination of Anti-Ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases.US2014323533A1. 2014.
78. Genzyme Corporation. Combination therapy for treating breast cancer.US8911736B2. 2014.
79. A.Dietrich Silivia. Total synthesis and biological activity of new functionalized epothilones for prodrug design and tumor targeting [dissertation submitted for Ph.D thesis]. Zurich: ETH Zurich; 2010.
80. Y.Xufen, D.Sun. Macrocyclic drugs and synthetic methodologies toward macrocycles. Molecules. 2013;18:6230–6268.
81. E.Kim, B.S.Moore, Y.J.Yoon. Reinvigorating natural product combinatorial biosynthesis with synthetic biology. Nat Chem Biol. 2015;11:649–659.
82. R.M.Borzilleri, X.Zheng, R.J.Schmidt, et al. A novel application of a Pd(0)-Catalyzed nucleophilic substitution reaction to the regio- and stereoselective synthesis of lactam analogues of the epothilone natural products. J Am Chem Soc. 2000;122:8890–8897.
83. S.R.Park, J.W.Park, W.S.Jung, et al. Heterologous production of epothilones B and D in Streptomyces venezuelae. Appl Microbiol Biotechnol. 2008 Nov;81(1):109–117.
84. S.R.Park, A.R.Han, Y.H.Ban, et al. Genetic engineering of macrolide biosynthesis: past advances, current state, and future prospects. Appl Microbiol Biotechnol. 2010 Feb;85(5):1227–1239.
85. J.Cortes, J.Baselga. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist. 2007;12(3):271–280.
86. E.S.Thomas, H.L.Gomez, R.K.Li, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210–5217.
87. D.M.Roque, E.S.Ratner, D.A.Silasi, et al. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. Gynecol Oncol. 2015;137(3):392–400.
88. B.Zhang, J.Carroll, J.Trojanowski, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci. 2012;32(11):3601–3611.